Partial Nephrectomy for Clinical T2 Renal Tumors: Current Evidence in Perspective

Mathew Yamoah Kyei and James Edward Mensah

Department of Surgery and Urology, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Ghana

^*Correspondance to: Mathew Yamoah Kyei 

 PDF  Full Text DOI: 10.25107/2474-1647.1709

Abstract

Renal tumor is one of the most important urological malignancies with a rising worldwide incidence. There is advocacy for nephron sparing surgery (Partial nephrectomy (PN)) in the management of renal tumors because of studies that have demonstrated impaired renal function after radical nephrectomy with an associated increased risk of overall mortality. Renal tumors with size less than 4 cm, clinical stage T1a (cT1a), had been the focus for PN. However currently, clinical stage T2 (cT2) renal tumors which are renal tumors larger than 7 cm but confined to the kidneys are being managed with partial nephrectomy. This expanding use has been attributed to advances in tumor biology, radiological imaging and surgical technology. We explore the current evidence in support of this emerging practice.

Keywords

Cite the article

Kyei MY, Mensah JE. Partial Nephrectomy for Clinical T2 Renal Tumors: Current Evidence in Perspective. Clin Surg. 2017; 2: 1709.